NCT02069041: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer |
|
|
| Completed | 1b | 8 | RoW | Ramucirumab, IMC-1121B, LY3009806, FOLFOX4, FOLFOX4 (leucovorin + fluorouracil + oxaliplatin) | Eli Lilly and Company | Carcinoma, Hepatocellular | 09/16 | 09/16 | | |
NCT00861783: Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma |
|
|
| Completed | 1 | 16 | US | irinotecan and ON 01910.Na, camptothecin-11, irinotecan HCl, Camptosar, CPT-11, diaminocyclohexane oxalatoplatinum, rigosertib sodium, oxaliplatin and ON 01910.Na, Eloxatin, oxaloplatinum, oxalatoplatin | Onconova Therapeutics, Inc. | Hepatoma, Advanced Solid Tumor | 07/11 | 07/11 | | |
| Completed | 1 | 10 | US | Oxaliplatin | David Bartlett, The Pittsburgh Foundation, Sanofi | Unresectable Colorectal Liver Metastases | 11/11 | 11/11 | | |
